Compare AERT & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AERT | ATRA |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | Singapore | United States |
| Employees | 1400 | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9M | 38.9M |
| IPO Year | N/A | 2014 |
| Metric | AERT | ATRA |
|---|---|---|
| Price | $0.74 | $10.19 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 130.3K | ★ 3.2M |
| Earning Date | 02-09-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.26 | $3.92 |
| 52 Week High | $1.52 | $19.15 |
| Indicator | AERT | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 69.87 | 68.65 |
| Support Level | $0.70 | $4.35 |
| Resistance Level | $0.83 | $12.91 |
| Average True Range (ATR) | 0.04 | 1.45 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 84.31 | 62.30 |
Aeries Technology Inc is a professional and management services partner offering a range of management consultancy services for private equity sponsors and their portfolio companies with engagement models that are designed to provide a mix of deep vertical specialty, functional expertise, and digital systems and solutions to scale, optimize and transform a client's business operations. It supports and drives its client's growth across the globe by providing a range of management consultancy services involving professional advisory services and operations management services to build and manage dedicated delivery centers in appropriate locations based on customer business needs.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).